Goldman Sachs
AKBA icon

Goldman Sachs’s Akebia Therapeutics AKBA Stock Holding History

Goldman Sachs’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-12,200
Closed -$166K – 5278
2020
Q2 		$166K Buy
+12,200
New +$126K ﹤0.01% 4856

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs's AKBA Position: Q2 2026 in Review

Goldman Sachs increased its Akebia Therapeutics (AKBA) stake by 2.4% in Q2 2026, buying an estimated $103K and bringing the position to 3,689,167 shares worth $4.21M. The position accounts for ﹤0.01% of the portfolio, ranked #4037.

Goldman Sachs first reported a position in AKBA in Q2 2015 and has held it in 43 quarters since. The position peaked at $15.4M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Goldman Sachs held 3,689,167 shares of Akebia Therapeutics worth $4.21M as of Q2 2026.
  • Goldman Sachs bought 86,340 Akebia Therapeutics shares in Q2 2026, an estimated $103K.
  • Akebia Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4037 holding.
  • Goldman Sachs first reported a position in Akebia Therapeutics in Q2 2015 and has held it in 43 quarters since.
  • Goldman Sachs's Akebia Therapeutics position peaked at $15.4M in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.